Physician profile
Steven E Caplan
NPI 1376516914
$3,397.25
in general payments reported to CMS, 2019-2025
27 companies · $674 in 2025
The $674 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $395 · 2021: $37.92 · 2022: $23.75 · 2023: $585 · 2024: $590 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823 · Education: $26.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.84 |
| Education | $26.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $595.93 | 2019-2025 | Tremfya |
| Abbvie INC. | $592.80 | 2019-2025 | Botox, Rinvoq, Skyrizi |
| Amgen INC. | $276.54 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $236.83 | 2019-2025 | |
| Lilly USA, LLC | $179.03 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $157.52 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $152.02 | 2023-2025 | Sotyktu |
| Ucb, INC. | $151.43 | 2020-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $151.29 | 2019-2024 | Dupixent |
| Genzyme Corporation | $116.39 | 2019 | |
| Janssen Scientific Affairs, LLC | $108.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.17 | 2023-2025 | Spevigo |
| Genentech USA, INC. | $73.12 | 2019-2020 | |
| Dermavant Sciences, INC. | $72.77 | 2023-2024 | Vtama |
| Celgene Corporation | $68.20 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $59.71 | 2019-2024 | |
| Galderma Laboratories, L.P. | $53.98 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $52.91 | 2020-2021 | |
| Dermira, INC. | $52.00 | 2019-2020 | |
| Organon LLC | $29.54 | 2023 | Hadlima |
| Janssen Pharmaceuticals, INC | $26.34 | 2025 | Tremfya |
| Helsinn Therapeutics (U.S.), INC. | $22.63 | 2020 | |
| Aclaris Therapeutics, INC. | $21.16 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.78 | 2019 | |
| Strata Skin Sciences, INC. | $14.43 | 2025 | Xtrac |
| Merck Sharp & Dohme LLC | $13.22 | 2019 | |
| Sanofi Pasteur INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Caplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.